REKVINA LAB.
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Events:
Split
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Rekvina Labs do?
Rekvina Laboratories Ltd is committed to provide quality medication at affordable prices to the patients with a view to help bring down the healthcare costs.
Who are the competitors of Rekvina Labs?
Rekvina Labs major competitors are . Market Cap of Rekvina Labs is ₹3 Crs. While the median market cap of its peers are ₹0 Crs.
Is Rekvina Labs financially stable compared to its competitors?
Rekvina Labs seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Rekvina Labs pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Rekvina Labs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Rekvina Labs allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Short Term Loans & Advances
How strong is Rekvina Labs balance sheet?
Rekvina Labs balance sheet is weak and might have solvency issues
Is the profitablity of Rekvina Labs improving?
No, profit is decreasing. The profit of Rekvina Labs is -₹0.14 Crs for Mar 2025, -₹0.02 Crs for Mar 2024 and ₹0 Crs for Mar 2023
Is the debt of Rekvina Labs increasing or decreasing?
Yes, The net debt of Rekvina Labs is increasing. Latest net debt of Rekvina Labs is ₹0.81 Crs as of Sep-25. This is greater than Mar-25 when it was ₹0.2 Crs.
Is Rekvina Labs stock expensive?
There is insufficient historical data to gauge this. Latest PE of Rekvina Labs is 0
Has the share price of Rekvina Labs grown faster than its competition?
Rekvina Labs has given lower returns compared to its competitors. Rekvina Labs has grown at ~-9.47% over the last 8yrs while peers have grown at a median rate of 0%
Is the promoter bullish about Rekvina Labs?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Rekvina Labs is 41.3% and last quarter promoter holding is 41.3%.
Are mutual funds buying/selling Rekvina Labs?
There is Insufficient data to gauge this.
